Health Canada / Santé Canada

Note to file
Note au dossier

Application Information / Information de soumission	
*Licence Name/Nom de l'homologation: **LYRA DIRECT SARS-COV-2 ASSAY**	Application Number/Numéro de soumission **312783**
Licence # / # de l'homologation: **0**	Application Type/Type de soumission: **Interim Order**
Manufacturer/Fabricant: **DIAGNOSTIC HYBRIDS, INC. - ALSO TRADING AS QUIDEL CORPORATION**	Company ID/Identificateur d'entreprise: **116717**
Risk Class: **3**	Rationale: **Classificaiton Rule IVDD Rule 2(b)(i)**
*Licence Type/Type d'homologation: **Test Kit**	Rationale:

☐ Contains Controlled Substance(s) ☐ Contains Drug(s) ☐ Contains Biological Material(s)

*Intended Use and/or Indications for Use/ Utilisation Prévue et/ou Indications

The Lyra Direct SARS-CoV-2 Assay is a real-time RT-PCR assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasal (NS), nasopharyngeal (NP), or oropharyngeal (OP) direct swab specimens from patients suspected of COVID-19 by their healthcare provider. The Assay targets the non-structural Polyprotein (pp1ab) of the SARS-CoV-2 virus.
Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 is generally detectable in upper respiratory specimens during the acute phase of infection Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or coinfection with other viruses. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.
Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions.
Negative results must be combined with clinical observations, patient history, and epidemiological information.
The Lyra Direct SARS-CoV-2 Assay is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures.

OEM Licence Information	
OEM Licence Name :	OEM Manufacturer :
OEM Intended Use and/or Indications for Use	

Reason for Change		Comment(s)
Change to classification of a device	☐	
Manufacturer name change	☐	
License name change	☐	
Device name change	☐	
Change to the purpose/indication of license	☐	
Addition of device(s)	☐	

Deletion of device(s)	☐	

Reason for Change		Comment(s)
Change in name and/or address of the Private Label Manufacturer	☐	
Private Label License name change	☐	
Private Label Device name change	☐	
Addition of device(s)	☐	
Deletion of device(s)	☐	

Certificate Screening Checklist:

Cert # (new):	Cert Revisions / Comments (If Applicable):
Cert. # (old):	
Replacing Existing Cert on File (Y/N):	

Criteria	conforms	Comments/info for MDS
Issued to full name of manufacturer as it appears on application/licence and label.	☐	
Issued to complete civic address matching application/licence and label.	☐	
Criteria are ISO 13485:2016 and Medical Devices Regulations – Part 1 – SOR 98/282	☐	
Scope activities limited to design, development, manufacture, production, servicing, installation, or distribution.	☐	
Activities include “manufacture” or “production” Activities include “design” or “development and development” for class III/IV devices.	☐	
Scope is unambiguous and covers app./lic. devices. Does not contain product names/models/licence numbers.	☐	
Auditing Organisation is Authorized or Recognized	☐	
Statement of Authorization or Recognition.	☐	
Field labelled “Effective Date”	☐	
Field labelled “Expiry Date”	☐	
Validity period ≤ 3 years	☐	
Unique identification code labelled “certificate number” or “certification document number”	☐	☐ new ☐ revised
Name, title, and signature of certification authority	☐	
Pagination (page x or y) included on all pages . All pages present.	☐	
Method to verify validity	☐	

Screening Decision

Health Canada / Santé Canada

Note to file
Note au dossier

Accept	
Jiazhen Minnie Dai Device Licensing Services Division Medical Devices Bureau	**Date**:2020-05-05

Health Canada Santé Canada

Note to file
Note au dossier

Check GMDN

GMDN Name	GMDN Code	GMDN Description	Issue	Action for Screener	Regulatory Action	Reference Material